CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Barclays Global Healthcare Conference on Thursday, March 17. The presentation will take place at 1:05 p.m. EDT.

Live audio webcast of the presentation will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres’ most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring Clostridium difficile infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160314005384/en/

Source: Seres Therapeutics, Inc.

Seres Therapeutics
IR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com
or
PR Contact:
Ten Bridge Communications
Dan Quinn, 781-475-7974
Dan@tenbridgecommunications.com